laboratory test results were as follows: C-reactive protein, 26.6 mg/dl; urea, 76.4 mg/dl; erythrocyte sedimentation rate, 36; white blood cell count, 16 .3×103/μL; and hemoglobin, 11.1 g/dL. Other laboratory findings were within normal limits. Abdominal ultrasonography showed that liver parenchyma echogenicity was compatible with grade 2-3 fatigue. Based on these findings, levofloxacin 500 mg/ day, salbutamol four times daily 100 mcg inhaler, enoxaparin twice daily 0.4 ml, methylprednisolone once daily 80 mg, furosemide twice daily 40 mg, and budesonide twice daily 100 mcg inhaler were added to the medical treatment of the patient along with the previous medications. Elevated levels of liver enzymes, especially GGT, were found in the patient's daily follow-up. ALT, AST, and LDH increased three times, and GGT increased approximately 35 times (Table 1) . It was estimated that the drug toxicity caused the elavation of GGT. Levofloxacin, amiodarone, atorvastatin, and metformin were discontinued. A week later, GGT reduced from 1900 to 637 U/L. Amiodarone 200 mg/day was started again to control the patient's heart rate. However, 5 days after the start of amiodarone, the GGT level increased to 877-910 U/L. In order to evaluate the side effect of the drug, the adverse effects related to the evaluation using the Council for International Organizations of Medical Sciences/the Roussel Uclaf Causality Assessment Method (CI-OMS/RUCAM) scale. Scale score was 10 points and this score shows ''highly probable'' adverse drug reaction. Therefore, amiodarone was stopped. Digoxin was added to control the patient's heart rate. The GGT level then decreased to 270 U/L. The pneumonia symptoms improved, edema decreased, and breathlessness improved. The patient was offered to come to the control and was discharged. The GGT level was found to be 66 U/L in the control examination of the patient approximately 2 months later.
Discussion
Long-term oral amiodarone treatment has several side effects such as thyroid dysfunction, photosensitivity, corneal microdeposits, pulmonary toxicity, and hepatotoxicity. [1] The frequency of drug side effects is related to total drug exposure. [1] Liver toxicity in these patients is usually transient and improves after dose reduction or discontinuation. [1] Amiodarone is removed by the bilious system. Because of the long half-life of amiodarone, the side effects sometimes continue for months after the drug is discontinued. Typical histological findings of amiodarone-associated acute hepatitis are steatohepatitis and phospholipidosis. [3, 4] The amiodarone can be caused by several mechanisms of phospholipidosis in the liver; first, amiodarone directly inhibits phospholipase enzyme (especially lysosomal phospholipase), and second, amiodarone binding to phospholipids leads to the formation of a drug-phospholipid complex that is more resistant to phospholipases. [9] [10] [11] These changes are similar to those found in alcoholic liver disease.
The presence of phospholipid-loaded lysosomal lamellar bodies on electron microscopy may aid in distinguishing amiodarone hepatotoxicity from alcoholic liver disease. [12] [13] [14] In this case, the duration of the use of amiodarone was approximately 6 months and the liver had stage 2-3 steatosis. It has been reported that the use of low-dose oral amiodarone (200 mg/daily) stimulated the formation of steatohepatitis. [8] In our present case, steatosis was thought to facilitate amiodarone toxicity. The criteria for establishing a causal relationship between amiodarone and hepatotoxicity are the exclusion of other drugs and non-drug causes, suspicion of drug initiation, improvement of drug release, and onset of drug hepatotoxicity again. [2] Different algorithms are used to determine the causal relationship between a drug and its side effects according to these criteria. [5] [6] [7] We used the CIOMS/RUCAM scales to assess drug-induced liver injury and the result from the scale was "highly probably" adverse drug reaction (Scale score was 10 points). [17, 18] Fonseca et al. [1] reported that ALT, AST, and LDH levels were increased to more than 50 times in amiodarone-induced hepatitis because of amiodarone and that GGT and ALP levels were normal. However, there is no study in the literature on the possibility of isolated GGT elevation.
GGT is found in biliary epithelial cells and hepatocytes. [15] Increased isolated GGT may be due to drug induction. However, amiodarone is a CYP1A2, CYP2C9, and CYP2D6 inhibitor. [16] Increased isolated GGT may be due to alcohol use. However, our patient did not consume alcohol. Histological changes in alcoholic liver disease and those in liver injury due to amiodarone toxicity are similar. [12] [13] [14] We think that the reason for the elevation of isolated GGT bound to amiodarone is related to this histological similarity.
Conclusion
The use of oral amiodarone is safer than intravenous amiodarone. There are several side effects along with the cumulative effect of long-term oral amiodarone Table 1 . Liver enzymes during treatment of the patient First day  54  21  100  13  243  Eighth day  83  17  70  11  290  Thirteenth day  304  38  56  15  363  Fifteenth day  1445  90  97  59  437  Nineteenth day 1977  80  164  64  411 therapy. However, it should not be forgotten that oral amiodarone-induced liver damage may occur early in patients with steatosis in the liver, as observed using ultrasonography. It may be thought that this liver damage may occur as an isolated GGT elevation at subject with steatohepatitis.
Duration of GGT (U/L) ALT (U/L) ALP (U/L) AST (U/L) LDH (U/L) hospitalization

